These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6096836)

  • 21. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?
    Costa E Silva JA
    Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ
    J Am Osteopath Assoc; 2007 Sep; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
    Radomska M; Pach J; Chrostek Maj J
    Przegl Lek; 2001; 58(4):351-3. PubMed ID: 11450367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Arrest of the painful syndrome by moradol and nubain in patients with ischemic heart disease].
    Litovchenko VS; Blinov AV
    Anesteziol Reanimatol; 1996; (4):30-1. PubMed ID: 8975566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Public policy statement on buprenorphine for opiate dependence and withdrawal.
    J Addict Dis; 2004; 23(4):116-7. PubMed ID: 15534969
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chronopharmacological features of the pain-relieving effects of analgesics].
    Kubynin AN; Ignatov ID
    Anesteziol Reanimatol; 1996; (4):7-9. PubMed ID: 8975577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of opiate dependence in hands of primary care providers.
    Public Health Rep; 2003; 118(1):76. PubMed ID: 12622131
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment options for opiate addiction.
    J Ky Med Assoc; 2004 May; 102(5):221-4. PubMed ID: 15152448
    [No Abstract]   [Full Text] [Related]  

  • 33. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ
    J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception.
    Fischer BD; Dykstra LA
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1300-6. PubMed ID: 16772537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
    Lubman D; Koutsogiannis Z; Kronborg I
    Drug Alcohol Rev; 2003 Dec; 22(4):433-6. PubMed ID: 14660133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine: effective treatment of opioid addiction starts in the office.
    Fiellin DA
    Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous nalbuphine 50 microg x kg(-1) is ineffective for opioid-induced pruritus in pediatrics.
    Nakatsuka N; Minogue SC; Lim J; Montgomery CJ; Court CA; Malherbe S; Csanyi-Fritz Y; Kearney RA; Phillips L; Reid K; Kingsley J; Ansermino JM
    Can J Anaesth; 2006 Nov; 53(11):1103-10. PubMed ID: 17079637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Basic research trends in the prevention of traumatic shock using pharmacological agents (2)].
    Dolinin VA; Vinogradov VM
    Voen Med Zh; 1982 Jan; (1):22-6. PubMed ID: 6277086
    [No Abstract]   [Full Text] [Related]  

  • 39. Spontaneous clearance of hepatitis C virus after long-term opiate dependence therapy with buprenorphine.
    Brunelle E; Ledru S; Rotily M; Becker C; Davion T; Vosgien V; Martinot M; Halfon P
    J Viral Hepat; 2004 Nov; 11(6):571-3. PubMed ID: 15500559
    [No Abstract]   [Full Text] [Related]  

  • 40. Buprenorphine: a primer for emergency physicians.
    Sporer KA
    Ann Emerg Med; 2004 May; 43(5):580-4. PubMed ID: 15111917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.